DIVIS LABORATORIES
Back to Balance Sheet
|
DIVIS LABORATORIES Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹1,215 Cr | ₹500 Cr | ₹611 Cr | ₹557 Cr | ₹437 Cr |
What is the latest Total Non-Current Liabilities ratio of DIVIS LABORATORIES ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹1,215 Cr |
| Mar2025 | ₹500 Cr |
| Mar2024 | ₹611 Cr |
| Mar2023 | ₹557 Cr |
| Mar2022 | ₹437 Cr |
How is Total Non-Current Liabilities of DIVIS LABORATORIES Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,215 Cr | 143.00 | |
| Mar2025 | ₹500 Cr | -18.17 | |
| Mar2024 | ₹611 Cr | 9.69 | |
| Mar2023 | ₹557 Cr | 27.60 | |
| Mar2022 | ₹437 Cr | - | |
Compare Total Non-Current Liabilities of peers of DIVIS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DIVIS LABORATORIES | ₹194,612.8 Cr | 0.6% | 8.7% | 7.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹470,786.0 Cr | 0.5% | 6.8% | 16.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,658.0 Cr | 0.4% | 13.8% | 46.9% | Stock Analytics | |
| CIPLA | ₹115,728.0 Cr | -0.4% | 5.8% | -2.9% | Stock Analytics | |
| MANKIND PHARMA | ₹106,460.0 Cr | 1.2% | 6.6% | -5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,708.0 Cr | -1.9% | -5.1% | -2.2% | Stock Analytics | |
DIVIS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | 0.6% |
8.7% |
7.9% |
| SENSEX | 0.5% |
0.1% |
-6.1% |
You may also like the below Video Courses